Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9149

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Live official records

Open in full search

Conditions: Heart Transplant
Interventions: Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium, Prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 76 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 4 more

Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Interventions: XmAb541; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: AFX3772, Prevnar 13, Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions: revumenib, cobicistat; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 30 Days and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 17 more

Conditions: HIV, STIs, STIs Prevention, HIV Prevention
Interventions: Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9; Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 24 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Risankizumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 44
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more

Conditions: Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
Interventions: Lifileucel; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: Tampa, Florida • New York, New York

Conditions: Colorectal Cancer
Interventions: Telisotuzumab Adizutecan, Standard of Care; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions: Azacitidine, Rezatapopt; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Conditions: Intracranial Aneurysm
Interventions: Artisse™ Intrasaccular Device; Device
Lead sponsor: Medtronic Neurovascular Clinical Affairs; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 25
States / cities: Los Angeles, California • Englewood, Colorado • New Haven, Connecticut + 21 more

Conditions: Rheumatoid Arthritis
Interventions: AZD1163, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Live official records

Belatacept in Heart Transplantation

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Combatting HIV Or Other STIs Early (CHOOSE)

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis